SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI.X is trending amid community excitement surrounding new listings on exchanges and potential partnerships, driving significant volume. The community is closely watching for a breakout, with many believing it has the potential to reach new all-time highs and drop a zero soon. Bullish sentiment is fueled by its association with Coinbase and the broader anticipation of altcoin season.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW.X) is trending as the community rallies around the coin's unique branding and potential. Active discussions highlight its multichain functionality and deflationary mechanisms. Community members are expressing excitement and encouraging others to join the "caw caw" movement.

Kangarhold is a meme-inspired crypto ecosystem built around the character KangaRHold (“Kanga” = short form; “Ranger” + “Hold”). The project explores internet culture through short-form video content such as funny animal moments, pranks, riddles, and gym clips published across its social channels. In addition to entertainment, Kangarhold actively collaborates with crypto-tools developing projects, including Anonymous Coding Cult (focused on Monero-based privacy tools) and supports early-stage blockchain projects, like a DEX tracker for Solana and Ethereum (to be launched). Revenue is generated through content, partnerships, and merchandise, then reinvested into platform development, token utility, awareness efforts, and community rewards.

Kangarhold

Kangarhold ($KANGA.X) is trending as the community rallies behind the crypto, emphasizing holding strong. Talk centers on its potential for outperformance within the Solana ecosystem, with many users signaling their entry into the token.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

PHUM.X is gaining attention as community members highlight its potential as an undiscovered "gem" within the Solana ecosystem. Investors are actively discussing accumulating the token early, drawing comparisons to other popular meme coins. The token's association with the Solana blockchain is a key talking point.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as the community rallies around this Solana-based meme coin and its 'Updog' namesake. Active discussions revolve around its strong community, long-term development, and potential for a meme-driven surge similar to other popular dog-themed tokens in the crypto space.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight potential ecosystem catalysts, including new projects building on the network and treasury companies accumulating SOL tokens. Conversations also mention staking rewards and anticipation for new highs, particularly if the broader crypto market continues its bullish momentum. Several meme tokens on the Solana network are also gaining traction within the community.

ARPA Network (ARPA) is a decentralized secure computation network built to improve the fairness, security, and privacy of blockchains. ARPA threshold BLS signature network serves as the infrastructure of verifiable Random Number Generator (RNG), secure wallet, cross-chain bridge, and decentralized custody across multiple blockchains.   ARPA was previously known as ARPA Chain, a privacy-preserving Multi-party Computation (MPC) network founded in 2018. ARPA Mainnet has completed over 224,000 computation tasks in the past years. Our experience in MPC and other cryptography laid the foundation for our innovative threshold BLS signature schemes (TSS-BLS) system design and led us to today’s ARPA Network.   Randcast, a verifiable Random Number Generator (RNG), is the first application that leverages ARPA as infrastructure. Randcast offers a cryptographically generated random source with superior security and low cost compared to other solutions. Metaverse, game, lottery, NFT minting and whitelisting, key generation, and blockchain validator task distribution can benefit from Randcast’s tamper-proof randomness.

ARPA Chain

ARPA Chain is trending as community members discuss its potential for a significant run, with some citing its technology and low market cap as factors. Investors are actively buying and holding, anticipating a breakout that could lead to substantial gains, possibly fueled by news or a catalyst. The community also mentions its potential as a strong buy with a possible surge in value.

Story is a purpose-built layer 1 blockchain designed specifically to onramp intellectual property (IP) to the blockchain and make it programmable.  Story tokenizes any type of IP; whether that’s an idea, an image, a real world asset, a song, an AI model, an NFT or anything in-between. By embedding usage terms, attribution, and royalty agreements directly into the blockchain, Story provides a transparent, decentralized solution for IP management. This enables IP holders to protect their work, collaborate on IP seamlessly, and unlock revenue opportunities in an AI-powered economy.

Story Protocol

Story Protocol ($IP.X) is trending as community members discuss its recent price action and potential for further gains, with some eyeing targets as high as $20 by the end of the year. Positive sentiment is fueled by news from the Origin Summit in South Korea and potential deals with major AI/robotics companies. Some investors are also drawing comparisons to other cryptocurrencies that have seen significant growth after being listed on Coinbase.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending as the community discusses its potential listing on Coinbase and compares it to other high-performing DEXs like $HYPE.X and $MYX.X. Some speculate on potential price targets, while others highlight the backing from notable investors and its potential for significant growth. Traders are closely watching for breakouts and potential new all-time highs.

Pitbull

Pitbull ($PIT.X) is trending as the community rallies around its unique, decentralized structure with no team wallet or presale, emphasizing its community-driven nature. Recent mentions of NFT and Metaverse projects, along with increased visibility on platforms like Dextools, are fueling excitement. The #PitbullToken community highlights its commitment to building and growing together, with some suggesting it has the potential to reach new heights.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?

The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Bright Minds Biosciences Stock Friday?

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.
read more...

Shares of nanocap Bright Minds Biosciences, Inc. (<a class="mention" data-mention="$DRUG" data-symbol-id="DRUG" href="https://stocktwits.com/symbol/DRUG" target="_blank">$DRUG</a>) surged 47% in pre-market trading on Friday, making it one of the top five trending tickers on Stocktwits.The spike followed the company’s announcement of a non-brokered private placement of common shares priced at $21.70 per share, Thursday’s closing price, with aggregate gross proceeds expected to reach up to $35 million.Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief, conducted in partnership with the National Institutes of Health’s pain screening program.In nerve ligation pain models, BMB-201 demonstrated efficacy comparable to morphine, exhibiting superior reductions in mechanical allodynia and pain-related behaviors.The company stated that BMB-201 might provide better pain relief than traditional opioid treatments while mitigating the risks of dependency and adverse side effects.With these encouraging preclinical results, Bright Minds plans to advance BMB-201 into clinical trials to further assess its safety and efficacy in human subjects.Additionally, Firefly Neuroscience ($AIFF) had also announced a collaboration with Bright Minds to analyze data from its first-in-human Phase 1 study of its lead compound, BMB-101.Earlier this week, DRUG became an <a href="https://stocktwits.com/news-articles/markets/equity/drug-stock-falls-pre-market-after-1500-percent-surge/cJczTIWR4H">unlikely top gainer</a> across U.S. exchanges, soaring over 1,440% without any apparent catalyst. This prompted the company to issue a statement noting it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”On Stocktwits, the retail following for DRUG has surged 125% over the past week, while message volume has skyrocketed by over 290 times in the past month.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/axp-stock-falls-premarket-after-q3-earnings/cJ22K06RIm">AmEx Stock Dips Pre-Market On Q3 Revenue Miss, But Retail Focuses On Bright Spots</a>

Bright Minds intends to allocate these funds toward research and development for its drug development programs, as well as general working capital.

Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief

Equity

Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief


Shares of Bright Minds Biosciences, Inc. ($DRUG) dropped by as much as 34% in pre-market trading on Wednesday after an enormous 1,445% surge in the previous session.Despite the apparent profit-booking, retail interest remains high.The Vancouver-incorporated biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”That was reportedly in response to a request from the Canadian Investment Regulatory Organization, which oversees trading on the company’s home exchange.On Stocktwits, DRUG was the top trending ticker early Wednesday, with message volume spiking nearly 2,500% in the previous session. Retail interest surged, with the stock gaining 71% more followers.<stembedurl>https://stocktwits.com/TheRealShortSqueezy/message/588993273</stembedurl><stembedurl>https://stocktwits.com/etrade/message/588956007</stembedurl>Pre-market trading volume as of 7:15 a.m. ET, Wednesday, was at about 600,000 shares, far exceeding the daily average of just 24,000.Bright Minds focuses on developing drugs targeting serotonin-mediated diseases, and recently started a Phase 2 trial for a treatment aimed at drug-resistant epilepsy.The company, which has yet to generate any revenue, in August reported a net loss of $1.8 million for the nine months ending June 30, 2024 — down significantly from a $5.8 million loss during the same period in 2023.With $6.2 million in cash and working capital of $6.1 million, it said it has sufficient funds to operate through 2026.As of Tuesday’s close, Bright Minds’ stock has gained 1,991% year-to-date.The sudden rise sent its market cap soaring from $4 million to nearly $172 million before the pre-market drop.

Bright Minds focuses on developing drugs targeting serotonin-mediated diseases.

Bright Minds Biosciences Stock Falls Pre-Market After Whopping 1,445% Gain, But Retail’s Still Hooked

The biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.” 

DRUG Stock Sees Profit-Booking Pre-Market After Massive 1,445% Gain, But Retail’s Still Hooked

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy

Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences Initiates the...

Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company was founded by Ian B. McDonald and Alan P. Kozikowski on May 31, 2019 and is headquartered in New York, NY.

Bright Minds Biosciences Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$52.22
Prev Close	$50.15
Open	$50.10
Dividend Yield	0.00%
50-Day Moving Average	$38.39
Beta	1.02
Avg. Volume	50,971.10
PE Ratio	-56.29

52-Week High	$79.02
52-Week Low	$0.94
Market Capitalization	$377.47M
EPS (Annual)	-$0.4777
Price to Book	9.94
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

DRUG
Bright Minds Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest DRUG News

DRUG Bright Minds Biosciences Inc